Global Pemphigus Vulgaris Treatment Market – Industry Trends and Forecast to 2030

Pemphigus Vulgaris Treatment Market Analysis and Size

Generally, patients have unexplained chronic mucosal ulceration, mainly with bullous skin lesions, have been suspected of having this condition. It is critical to differentiate pemphigus vulgaris treatment from other bullous dermatoses. Two specific clinical findings for PV include the Nikolsky sign and Asboe-Hansen sign. The diagnosis of this condition is confirmed by biopsy of lesion and surrounding normal skin. Immunofluorescence testing shows IgG autoantibodies against the keratinocyte's cell surface.

Data Bridge Market Research analyses a growth rate in the global pemphigus vulgaris treatment market in the forecast period 2023-2030. The expected CAGR of global pemphigus vulgaris treatment market tend to be around 8.50% in the mentioned forecast period. The market was valued at USD 414.74 million in 2022 and it would grow upto USD 796.55 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Pemphigus Vulgaris Treatment Market Scope and Segmentation

Market Definition

Pemphigus vulgaris treatment is a rare autoimmune disease that causes painful intraepithelial blistering on the skin and mucous membrane. The primary lesion or blister of pemphigus vulgaris treatment is a soft blister filled with clear fluid that arises on the healthy skin or an erythematous base. Several cases start with blister in mouth, followed by skin blisters and continue go on other parts of the body such as throat, eyes, lungs and others where mucous membranes are present. Pemphigus vulgaris treatment incidence ranges from 0.5-3.2 cases per 100,000 populations with a death rate of approximately 5-15%

Global Pemphigus Vulgaris Treatment Market Dynamics

Drivers

• Growing Incidence of Pemphigus Vulgaris treatment

Pelagius condition affects around 2,500 persons in the U.S, as per the International Pemphigus and Pemphigoid Foundation (IPPF). Additionally, it was discovered that there were 40,000 to 50,000 cases of pemphigus in the globe in the year 2017. Thus, it acts as a major driver in the market growth.

• Increase in the number of R&D activities       

Moreover, the market's growth is fueled by the rise in the number of R&D activities. This will provide much beneficial opportunities for the global pemphigus vulgaris treatment market. To encourage several researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives.

Opportunities

• Increased Demands of Treatment Methods

Treatment methods such as corticosteroids, because of their rapid effect is, helping patients with the fastest recovery. Systemic corticosteroids can also be used with immunosuppressive agents such as Azathioprine, Mycophenolate mofetil, Rituximab, in cases where there are expected complications of hypertension, diabetes mellitus, or osteoporosis due to prolonged use (>4 months) of the steroids. All these factors are also contributing in the growth of the market.  

Restraints/Challenges

• Lack of Awareness

The sales of potential products are not succeeding much because of the lack of awareness of the syndrome. Though effective treatments are available, but beliefs, poor inadequate communication between clinicians and patients, treatment adherence are the factors hindering the market growth.

• High Cost

The huge expenditure that is associated with the treatment processes hamper the market growth. Numerous market players make huge investments in installing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.

This global pemphigus vulgaris treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global pemphigus vulgaris treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Pemphigus Vulgaris Treatment Market Scope

The global pemphigus vulgaris treatment market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Corticosteroids
• Immunosuppressive
• Intravenous Immunoglobulin
• Antibiotics, Antivirals
• Antifungals
• Others

Route of Administration

• Oral
• Parenteral
• Topical
• Others

End-User

• Hospitals
• Research Institutes
• Specialty Clinics

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Pemphigus Vulgaris Treatment Market Regional Analysis/Insights

The global pemphigus vulgaris treatment market is analyzed and market size insights and trends are provided by treatment, distribution channel, route of administration, and end-user as referenced above.

The major countries covered in the global pemphigus vulgaris treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the market in the forecast period because of the presence of key manufacture of the product, high research and development, healthcare expenditure, and skilled professionals.

Asia-Pacific is considered to have the most lucrative period because of the increased government awareness programs and number of generic drugs. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Pemphigus Vulgaris Treatment Market Share Analysis

The global pemphigus vulgaris treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global pemphigus vulgaris treatment market

Key players operating in the global pemphigus vulgaris treatment market include:

• Pfizer Inc. (U.S.)
• Abbvie Inc. (U.S.)
• Novartis AG (Switzerland)
• Amgen Inc. (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Merck & Co Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• AstraZeneca (U.K.)
• Lilly (U.S.)
• Zydus Group (India)
• Fresenius Kabi AG (Germany)
• Accord Healthcare, Inc. (U.S.)

SKU-56081